- Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer2020 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries2017 | Faculty of Medicine in Pilsen
- Prognostic Factors After Surgical Treatment of Liver Metastases from Breast Cancer-19 Years of Experience2021 | Faculty of Medicine in Pilsen
- Management of HER2-positive breast cancer, escalation and de-escalation of the therapy2017 | First Faculty of Medicine
- Radiotherapy in the treatment of advanced breast cancer2014 | Third Faculty of Medicine
- Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success2014 | First Faculty of Medicine, Third Faculty of Medicine
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysisPublication without faculty affiliation
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial2017 | Publication without faculty affiliation